Migraine Stopper-Band

HealthCare Technology Innovation
HEALTH CARE OPRTNS/INFO TECHNOLOGY

Technology Created by SDSP INC

Table of contents: 1. Disease description and unmet needs 2 2. Current Treatments 2 3. Migraine Stopper-Band 3 4. Clincal and Economic benefits 3 5. Pricing Model 4 6. Market Access and Expansion Strategies 4 7. References 5
Migraine and other benign recurrent headache disorders are a major public health problem.They are associated with substantial personal suffering, disabil- ity, and societal expense.
1
In the United States, a number of public health surveillance systems and pri- vately funded studies have collected information on the prevalence, impact, and treatment of headache and migraine.
Disease Description and Unmet needs
Migraine and other benign recurrent headaches are a major public health problem. They are associated with substantial personal suffering, disability and societal expense. Migraine is considered a chronic disorder with episodic attacks [1], with two major subtypes differentiated based on attack frequency. Episodic migraine is characterized by attacks that occur fewer than 15 days per month. Chronic migraine is broadly defined by the presence of migraine in a person with headaches on at least 15 days per month. Diagnosis of primary headache disorders is primarily based on the presence, frequency, and severity of clinical features used to create diagnostic boundaries. Diagnostic tests serve to exclude secondary causes of headache, and biological markers mainly serve to gain insight into mechanisms.
Migraine affects roughly 12% of the adults in occidental countries.1,2 In US population studies, the prevalence of migraine is approximately 18% in women and 6% in men.3-5 Approximately 90% of the migraines have moderate or severe pain, three quarters have a reduced ability to function during the headache attacks, and one-third require bed rest during their attacks.6-9
Migraine is also undertreated in the United States; though most studies have focused on acute treatment.6-9 most migraineurs treat their headaches with acute treatments to the exclusion of preventive drugs.5, 10, 11 Patterns of use for migraine preventive treatment have rarely been studied in population samples.

Migraine is more common than many other chronic, disabling conditions. Its prevalence equals that of asthma and diabetes combined. * Rheumatoid arthritis affects 2.1 million Americans, mostly women. * Asthma affects an estimated 14.6 million American adults, has an overall lifetime prevalence of 10.5%, and affects women more than men. * Diabetes affects 17 million Americans, or 6.2% of the population. * Osteoarthritis affects 20.7 million Americans and women more than men. * Severe migraine affects 27.9 million Americans with a female to male ratio of 3 to 1.

Current Treatments

Migraine Stopper-Band
This headband acts as a small nerve-stimulating device and is to be worn as a regular headband. The lead tip of the band is in close proximity with SPG bundle, and when a patient senses the onset of a headache, he/she places a handheld small switch at the right part of the band that will display a small red signal.The resulting signals stimulate the SPG nerves and block the pain-causing neurotransmitters. This Product is user friendly and does not need any one else’s assitance for effective operation. This band once worn sits firmly against the nerves. When patients feel headaches coming on, they simply push the small swtich tweeking ‘red’ that sends a radio signal to the headband. This triggers a slight electrical charge to stimulate nerve cells. The patient can turn it on and off as needed. Moreover, the patient can leave it as is or take it out, when no longer necessary.